![HealthTree Podcast for Multiple Myeloma artwork](https://is5-ssl.mzstatic.com/image/thumb/Podcasts113/v4/8f/ab/bd/8fabbdcd-0da0-0239-dac5-df547f82810a/mza_6724809222047263023.jpg/100x100bb.jpg)
Myeloma Crowd Radio: Peter Voorhees, MD, Levine Cancer Institute
HealthTree Podcast for Multiple Myeloma
English - May 18, 2021 14:00 - 1 hour - 29.1 MB - ★★★★★ - 13 ratingsHealth & Fitness myeloma multiple myeloma Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
Myeloma experts are beginning to use antibodies in earlier lines of myeloma treatment, even for newly diagnosed patients. Learn what recent clinical trials are using antibody therapies such as daratumumab and isatuximab in early quad (four) drug combinations for newly diagnosed patients. Peter Voorhees of the Levine Cancer Institute joins Myeloma Crowd Radio to share his experience and findings from these clinical trials. He will discuss the early use and their use as maintenance therapy following stem cell transplant. Is earlier use better? Should they be "saved" for later? When should patients consider using the monoclonal antibodies as maintenance therapy with or without traditional drugs like lenalidomide? Dr. Voorhees will help answer these very practical questions for the myeloma community.
Thanks to our episode sponsor, Karyopharm Therapeutics.